Page 37 - Journal of Structural Heart Disease Volume 5, Issue 6

261
Original Scientific Article
Conflict of Interest
The authors have no conflict of interest relevant to this publication.
Comment on this Article or Ask a Question
References
1. Nkomo VT, Gardin JM, Skelton TN, Gottdiener JS, Scott CG, Enriquez-Sara- no M. Burden of valvular heart diseas- es: a population-based study. Lancet. 2006;368:1005–1011. DOI: 10.1016/S0140- 6736(06)69208-8
2. Carabello BA, Paulus WJ. Aortic stenosis. Lancet. 2009;373:956–966. DOI: 10.1016/ S0140-6736(09)60211-7
3. Bhattacharyya S, Hayward C, Pepper J, Se- nior R. Risk stratification in asymptomatic severe aortic stenosis: a critical apprais- al. Eur Heart J. 2012;33:2377–2387. DOI: 10.1093/eurheartj/ehs190
4. Nishimura RA, Otto CM, Bonow RO, Car- abello BA, Erwin JP, Guyton RA, et al. 2014 AHA/ACC guideline for the man- agement of patients with valvular heart disease: executive summary. Circula- tion. 2014;129:2440–2492. DOI: 10.1161/ CIR.0000000000000029
5. Grube E, Schuler G, Buellesfeld L, Gerckens U, Linke A, Wenaweser P, et al. Percutane- ous aortic valve replacement for severe aortic stenosis in high-risk patients using the second- and current third-generation self-expanding corevalve prosthesis. J Am Coll Cardiol. 2007;50:69–76. DOI: 10.1016/j. jacc.2007.04.047
6. Grube E, Buellesfeld L, Mueller R, Sauren B, Zickmann B, Nair D, et al. Progress and cur- rent status of percutaneous aortic valve re- placement: results of three device genera- tions of the corevalve revalving system. Circ Cardiovasc Interv. 2008;1:167–175. DOI: 10.1161/CIRCINTERVENTIONS.108.819839
7. Arora S, Ramm CJ, Misenheimer JA, Vaval- le JP. TAVR in Intermediate-Risk Patients: A review of the PARTNER 2 trial and its future implications. J Heart Valve Dis. 2016;25:653–656. PMID: 28290162
8. Kapadia SR, Leon MB, Makkar RR, Tuzcu EM, Svensson LG, Kodali S, et al. 5-year outcomes of transcatheter aortic valve re- placement compared with standard treat- ment for patients with inoperable aortic stenosis (PARTNER 1): a randomised con- trolled trial. Lancet. 2015;385:2485–2491. DOI: 10.1016/S0140-6736(15)60290-2
9. Allen LA, Rumsfeld JS. Can we predict
who will be alive and well after transcath- eter aortic valve replacement? Is that useful to individual patients? Circulation. 2014;129:2636–2637. DOI: 10.1161/CIRCU- LATIONAHA.114.010516
10. Holmes DR, Mack MJ, Kaul S, Agnihotri A, Alexander KP, Bailey SR, et al. 2012 ACCF/ AATS/SCAI/STS expert consensus docu- ment on transcatheter aortic valve replace- ment. J Am Coll Cardiol. 2012;59:1200– 1254. DOI: 10.1016/j.jacc.2012.01.001
11. Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, et al. Transcatheter valve implantation for patients with aor- tic stenosis: a position statement from the European Association of Cardio-Thoracic Surgery (EACTS) and the European Society of Cardiology (ESC), in collaboration with the European Association of Percutane- ous Cardiovascular Interventions (EAP- CI). Eur Heart J. 2008;29:1463–1470. DOI: 10.1016/j.ejcts.2008.04.039
12. Reynolds MR, Magnuson EA, Wang K, Thourani VH, Williams M, Zajarias A, et al. Health-related quality of life after transcatheter or surgical aortic valve replacement in high-risk patients with severe aortic stenosis. J Am Coll Car- diol. 2012;60:548–558. DOI: 10.1016/j. jacc.2012.03.075
13. Pibarot P, Hahn RT, Weissman NJ, Monaghan MJ. Assessment of paraval- vular regurgitation following tavr. Jacc cardiovasc imaging. 2015;8:340–360. DOI: 10.1016/j.jcmg.2015.01.008
14. Holmes DR, Brennan JM, Rumsfeld JS, Dai D, O’Brien SM, Vemulapalli S, et al. Clinical outcomes at 1 year following transcatheter aortic valve replacement. JAMA. 2015;313:1019. DOI: 10.1001/ jama.2015.1474
15. Reardon MJ, Adams DH, Kleiman NS, Yakubov SJ, Coselli JS, Deeb GM, et al. 2-year outcomes in patients undergoing surgical or self-expanding transcatheter aortic valve replacement. J Am Coll Car- diol. 2015;66:113–121. DOI: 10.1016/j. jacc.2015.05.017
16. Dweck MR, Joshi S, Murigu T, Alpendur- ada F, Jabbour A, Melina G, et al. Midwall
fibrosis is an independent predictor of mortality in patients with aortic stenosis. J Am Coll Cardiol. 2011;58:1271–1279. DOI: 10.1016/j.jacc.2011.03.064
17. Lafitte S, Perlant M, Reant P, Serri K, Douard H, DeMaria A, et al. Impact of impaired myocardial deformations on exercise tol- erance and prognosis in patients with asymptomatic aortic stenosis. Eur J Echo- cardiogr. 2009;10:414–419. DOI: 10.1093/ ejechocard/jen299
18. Assayag P, Carré F, Chevalier B, Delcayre C, Mansier P, Swynghedauw B. Compensated cardiac hypertrophy: arrhythmogenicity and the new myocardial phenotype. I. Fi- brosis. Cardiovasc Res. 1997;34:439–444. PMID: 9231026
19. Azevedo CF, Nigri M, Higuchi ML, Pomer- antzeff PM, Spina GS, Sampaio RO, et al. Prognostic significance of myocardial fibrosis quantification by histopatholo- gy and magnetic resonance imaging in patients with severe aortic valve disease. J Am Coll Cardiol. 2010;56:278–287. DOI: 10.1016/j.jacc.2009.12.074
20. Yilmaz A, Kindermann I, Kindermann M, Mahfoud F, Ukena C, Athanasiadis A, et al. Comparative evaluation of left and right ventricular endomyocardial biopsy. Circu- lation. 2010;122:900–909. DOI: 10.1161/ CIRCULATIONAHA.109.924167
21. Cengiz B, Sahin ST, Yurdakul S, Kahraman S, Bozkurt A, Aytekin S. Subclinical left ventricular systolic dysfunction in patients with severe aortic stenosis: A speckle track- ing echocardiography study. Turk Kardiyol Dern Ars. 2018;46:18-24. DOI: 10.5543/ tkda.2017.43037
22. Blessberger H, Binder T. Two dimensional speckle tracking echocardiography: clin- ical applications. Heart. 2010;96:2032– 2040. DOI: 10.1136/hrt.2010.199885
23. Sugimoto T, Dulgheru R, Bernard A, Ilardi F, Contu L, Addetia K, et al. Echocardiograph- ic reference ranges for normal left ven- tricular 2D strain: results from the EACVI NORRE study. Eur Hear J - Cardiovasc Imag- ing. 2017;18:833–840. DOI: 10.1093/ehjci/ jex140
24. Kalam K, Otahal P, Marwick TH. Prognos-
Hemu M. et al.
Strain Analysis Predicts Mortality in Post-TAVR Patients